SEC Tracker
Get the app

Pacira BioSciences PCRX

Pacira BioSciences to be acquired by Viatris

SC14D9C filing

Form
SC14D9C
Filed
Importance
Routine
  1. Viatris to acquire Pacira for $36.50 per share in cash
  2. Transaction expected to close by end of 2026
  3. Pacira's portfolio and pipeline to become part of Viatris's innovative medicines
  4. Employees to remain focused on Q4 goals until transaction closes

Written from the SC14D9C on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Pacira BioSciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Phibro Animal Health PAHC public float $764M, Dec 31, 2025
  2. Syndax Pharmaceuticals SNDX public float $799M, Jun 30, 2025
  3. Geron GERN public float $861M, Jun 30, 2025
  4. Anaptysbio ANAB public float $633M, Dec 31, 2025
  5. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025